CN102985548B - 用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物 - Google Patents

用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物 Download PDF

Info

Publication number
CN102985548B
CN102985548B CN201080031986.9A CN201080031986A CN102985548B CN 102985548 B CN102985548 B CN 102985548B CN 201080031986 A CN201080031986 A CN 201080031986A CN 102985548 B CN102985548 B CN 102985548B
Authority
CN
China
Prior art keywords
nucleic acid
composition
solution
cationic lipid
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080031986.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102985548A (zh
Inventor
崔坤元
梁东
大卫·斯威德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102985548A publication Critical patent/CN102985548A/zh
Application granted granted Critical
Publication of CN102985548B publication Critical patent/CN102985548B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201080031986.9A 2009-05-16 2010-05-16 用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物 Active CN102985548B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17896209P 2009-05-16 2009-05-16
US61/178,962 2009-05-16
PCT/US2010/035049 WO2010135207A1 (en) 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules

Publications (2)

Publication Number Publication Date
CN102985548A CN102985548A (zh) 2013-03-20
CN102985548B true CN102985548B (zh) 2016-10-26

Family

ID=43126456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080031986.9A Active CN102985548B (zh) 2009-05-16 2010-05-16 用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物

Country Status (7)

Country Link
US (1) US9080186B2 (https=)
EP (1) EP2430168B1 (https=)
JP (1) JP5675784B2 (https=)
CN (1) CN102985548B (https=)
AU (1) AU2010249881B2 (https=)
CA (1) CA2762095A1 (https=)
WO (1) WO2010135207A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027809A1 (zh) 2022-08-05 2024-02-08 厦门甘宝利生物医药有限公司 一种抑制apoc3基因表达的rna抑制剂及其应用
WO2024088190A1 (zh) 2022-10-24 2024-05-02 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
IN2012DN00570A (https=) 2009-07-14 2015-06-12 Polypid Ltd
CN102892406B (zh) 2010-01-19 2015-04-08 波利皮得有限公司 缓释核酸基质组合物
FR2994849B1 (fr) * 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents
FR2998899B1 (fr) 2012-11-30 2015-07-17 Commissariat Energie Atomique Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques
US10253315B2 (en) 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
EP2719765A1 (de) * 2012-10-11 2014-04-16 Secutech International Pte. Ltd. Ex vivo-Verfahren zur Einbringung von Nukleinsäuren in Zellen
ES2733998T3 (es) * 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9889200B2 (en) * 2013-07-31 2018-02-13 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
WO2015184326A1 (en) * 2014-05-30 2015-12-03 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20150368648A1 (en) 2014-06-20 2015-12-24 Yale University Compositions and methods of inhibiting gene expression in a lung
KR101671864B1 (ko) * 2014-08-29 2016-11-04 세종대학교 산학협력단 요오드화 오일을 함유하는 양이온성 에멀젼 및 바이러스 벡터의 유전자 전달 증진을 위한 이의 용도
CN104922141B (zh) * 2015-05-28 2016-05-25 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的siRNA组合物
CN105079021A (zh) * 2015-08-03 2015-11-25 厦门成坤生物技术有限公司 包含m10c1化合物与活性成分的组合物及其制备方法
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
CN108779074A (zh) * 2016-03-01 2018-11-09 分子传递有限公司 植物病毒移动蛋白和其使用方法
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11969506B2 (en) * 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
CN107802508A (zh) * 2017-11-01 2018-03-16 武汉百思凯瑞纳米科技有限公司 一种阳离子脂质体纳米组合物及其制备方法和应用
KR102056144B1 (ko) 2018-03-08 2019-12-16 주식회사 파마리서치프로덕트 Dna 단편 혼합물이 고농도로 함유된 유동성을 갖는 액제 조성물 및 이의 제조방법
EP3852764A4 (en) * 2018-09-19 2022-06-15 ModernaTX, Inc. STEROL ANALOGUES AND USES THEREOF
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061317A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. Sterol purification
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN111904934B (zh) * 2020-09-21 2022-02-25 中国医学科学院医药生物技术研究所 miRNA185抑制剂的脂质体及其制法
CN120775847A (zh) 2021-10-20 2025-10-14 厦门甘宝利生物医药有限公司 Agt抑制剂及其用途
WO2023176822A1 (ja) * 2022-03-15 2023-09-21 富士フイルム株式会社 化合物および脂質組成物
JPWO2023229023A1 (https=) * 2022-05-25 2023-11-30
CN115197431B (zh) * 2022-09-15 2022-11-29 清华大学 脂质偶联完全可降解水溶性聚合物的合成及应用
CN121568686A (zh) * 2023-07-24 2026-02-24 北京生命科学研究所 用于皮肤疾病局部治疗的脂质纳米颗粒组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044147A1 (en) * 1995-05-26 2001-11-22 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US20020102297A1 (en) * 1996-12-06 2002-08-01 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and using
US20050175682A1 (en) * 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20080299177A1 (en) * 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511069A (en) 1981-06-04 1985-04-16 The Pharmasol Corporation Dispensing system
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー.ファウ. 修飾リボザイム
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
ATE219660T1 (de) 1994-09-30 2002-07-15 Inex Pharmaceuticals Corp Mittel zum einbringen polyanionischer materialien in zellen
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) * 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
AU5911899A (en) 1998-09-09 2000-03-27 Genzyme Corporation Methylation of plasmid vectors
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
ES2559828T3 (es) * 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2011084721A2 (en) 2009-12-21 2011-07-14 Agave Pharma Inc Cationic molecule and method of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044147A1 (en) * 1995-05-26 2001-11-22 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US20020102297A1 (en) * 1996-12-06 2002-08-01 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and using
US20050175682A1 (en) * 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
CN1882693A (zh) * 2003-09-15 2006-12-20 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US20080299177A1 (en) * 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027809A1 (zh) 2022-08-05 2024-02-08 厦门甘宝利生物医药有限公司 一种抑制apoc3基因表达的rna抑制剂及其应用
WO2024088190A1 (zh) 2022-10-24 2024-05-02 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用

Also Published As

Publication number Publication date
CA2762095A1 (en) 2010-11-25
JP2012526858A (ja) 2012-11-01
US9080186B2 (en) 2015-07-14
WO2010135207A1 (en) 2010-11-25
AU2010249881A1 (en) 2012-01-19
US20120289584A1 (en) 2012-11-15
JP5675784B2 (ja) 2015-02-25
AU2010249881B2 (en) 2015-01-22
CN102985548A (zh) 2013-03-20
EP2430168A4 (en) 2013-11-27
EP2430168B1 (en) 2016-12-21
EP2430168A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
CN102985548B (zh) 用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物
JP7422977B2 (ja) メッセンジャーrna用乾燥粉末製剤
CN103189057B (zh) 大环脂类化合物及其应用
KR102380363B1 (ko) Rna 전달을 위한 이온성 양이온 지질
CN110337429B (zh) 用于rna递送的可离子化阳离子脂质
US10556861B2 (en) Ionizable cationic lipid for RNA delivery
DK2494993T3 (en) Amino acid lipids and uses thereof
KR101762466B1 (ko) 지질, 지질 조성물 및 이의 사용 방법
CN102231979B (zh) 基因沉默治疗剂的脂质体有效递送方法和组合物
JP2022512945A (ja) 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む2,5-ジオキソピペラジン脂質
CN112533909A (zh) 维生素阳离子脂质
CN112424214A (zh) 包含甾族部分的阳离子脂质
KR20190039347A (ko) 활성제의 전달을 위한 생분해성 지질
EP0833667A1 (en) Stabilization of polynucleotide complexes
WO2025011532A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
WO2025051994A1 (en) Ionizable lipid nanoparticles
EP4306133A1 (en) Composition for administration of double-stranded oligonucleotide structures using ultrasonic nebulizer for prevention or treatment of respiratory viral infection including covid-19, pulmonary fibrosis caused by viral infection, or respiratory diseases
CN121426768A (zh) 一种化合物、lnp组合物、药用组合物及其应用
CN121135600A (zh) 可电离脂质化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant